Compare American International Group Inc (AIG) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs BioNano Genomics Inc — how do they compare? American International Group Inc trades at $76.46 (market cap $40.42B), while BioNano Genomics Inc trades at $1.19 (market cap $13.66M). The key difference: American International Group Inc is far larger — about 2959× BioNano Genomics Inc's market cap, and American International Group Inc pays a 2.59% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AIG | BNGO | |
|---|---|---|
Market Cap | $40.42B | $13.66M |
Sector | Financials | Health |
52-Week High | $86.59 | $4.92 |
52-Week Low | $71.89 | $1.06 |
Enterprise Value | $48.06B | $16.26M |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $76.42, down 1.53% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with $2.11 EPS versus $1.89 expected, driven by robust underwriting income. Revenue for 2025 was $26.77B with net income of $3.10B, yielding an 11.12% net margin. The stock carries a P/E of 14.11 and a consensus analyst price target of $89.00, suggesting potential upside from current levels.
The outlook for AIG is mixed; solid earnings performance and a diversified insurance portfolio support growth, but competitive pricing pressure and investment income headwinds pose risks. With 39% of analysts rating it a Buy, the stock appears undervalued relative to its price target, though near-term catalysts may be limited amid broader market volatility.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
